IL150368D0 - Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use - Google Patents

Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use

Info

Publication number
IL150368D0
IL150368D0 IL15036800A IL15036800A IL150368D0 IL 150368 D0 IL150368 D0 IL 150368D0 IL 15036800 A IL15036800 A IL 15036800A IL 15036800 A IL15036800 A IL 15036800A IL 150368 D0 IL150368 D0 IL 150368D0
Authority
IL
Israel
Prior art keywords
nitrosated
inhibitors
compositions
methods
use
Prior art date
Application number
IL15036800A
Original Assignee
Nitromed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US17162399P priority Critical
Priority to US22608500P priority
Application filed by Nitromed Inc filed Critical Nitromed Inc
Priority to PCT/US2000/035014 priority patent/WO2001045703A1/en
Publication of IL150368D0 publication Critical patent/IL150368D0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333Radicals substituted by oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58One oxygen atom, e.g. butenolide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/12Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 3 and unsubstituted in position 7
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
IL15036800A 1999-12-23 2000-12-22 Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use IL150368D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US17162399P true 1999-12-23 1999-12-23
US22608500P true 2000-08-18 2000-08-18
PCT/US2000/035014 WO2001045703A1 (en) 1999-12-23 2000-12-22 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use

Publications (1)

Publication Number Publication Date
IL150368D0 true IL150368D0 (en) 2002-12-01

Family

ID=26867270

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15036800A IL150368D0 (en) 1999-12-23 2000-12-22 Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use

Country Status (14)

Country Link
US (4) US6649629B2 (en)
EP (1) EP1246621A4 (en)
JP (1) JP2003523958A (en)
KR (1) KR20020067574A (en)
CN (1) CN100486573C (en)
AP (1) AP200202582A0 (en)
AU (1) AU782971B2 (en)
BR (1) BR0017037A (en)
CA (1) CA2393724A1 (en)
IL (1) IL150368D0 (en)
MX (1) MXPA02006312A (en)
NZ (1) NZ519781A (en)
RU (1) RU2002119574A (en)
WO (1) WO2001045703A1 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
WO1996001272A1 (en) * 1994-07-01 1996-01-18 Rican Limited Helicobacter proteins and vaccines
ES2283012T3 (en) * 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Helicobacter pylori bacterioferritine.
US20050137191A1 (en) * 1996-06-04 2005-06-23 Thatcher Gregory R. Nitrate esters and their use for mitigating cellular damage
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
US8519005B2 (en) 2000-07-27 2013-08-27 Thomas N. Thomas Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
CA2393724A1 (en) * 1999-12-23 2001-06-28 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
GB0002336D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
AU6124401A (en) * 2000-05-09 2001-11-20 Nitromed Inc Infrared thermography and methods of use
US6601580B1 (en) 2000-06-28 2003-08-05 The General Hospital Corporation Enhancing therapeutic effectiveness of nitric oxide inhalation
IT1319202B1 (en) * 2000-10-12 2003-09-26 Nicox Sa Drugs for diseases with inflammatory base.
SE0004229D0 (en) * 2000-11-17 2000-11-17 Aga Ab Inhalation of nitric oxide
JP4092203B2 (en) * 2000-12-21 2008-05-28 ニトロメッド,インク. Substituted aryl compounds, compositions, and methods of use as novel cyclooxygenase 2-selective inhibitors
US20040192600A1 (en) * 2001-08-01 2004-09-30 Dietrich Hafner Combination of selective cox-2 inhibitor and lung surfactant for respiratory syndrome
CA2458854A1 (en) * 2001-08-31 2003-03-06 Chiron Srl Helicobacter pylori vaccination
AU2003223491A1 (en) * 2002-04-05 2003-10-27 Nitromed, Inc. Nitric oxide donors, compositions and methods of use
US20060040945A1 (en) * 2002-05-17 2006-02-23 Merckle Gmbh Annellated pyrrole compounds as proton pump inhibitors for treating ulcer
WO2003103602A2 (en) 2002-06-11 2003-12-18 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
ITMI20021391A1 (en) 2002-06-25 2003-12-29 Nicox Sa Nitro-derivatives of cyclooxygenase-2 inhibitors
US20040127537A1 (en) * 2002-06-26 2004-07-01 Gokarn Yatin R. Stable liquid parenteral parecoxib formulation
EP1534683A4 (en) * 2002-06-27 2005-08-24 Nitromed Inc Cyclooxygenase-2 selective inhibitors, compositions and methods of use
AU2003279622A1 (en) * 2002-06-28 2004-01-19 Nitromed, Inc. Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
US7199154B2 (en) 2002-07-26 2007-04-03 Merck Frosst Company Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
JP2005538110A (en) * 2002-07-29 2005-12-15 ニトロメッド インコーポレーティッド Cyclooxygenase-2 selective inhibitors, compositions and methods of use
PA8578101A1 (en) * 2002-08-13 2004-05-07 Warner Lambert Co Heterobiaryl derivatives as inhibitors of matrix metalloproteinase
EP1546128B1 (en) 2002-08-19 2006-05-03 Glaxo Group Limited Pyrimidine derivatives as selective cox-2 inhibitors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
AU2004275777A1 (en) * 2003-09-24 2005-04-07 Combinatorx, Incorporated Therapeutic regimens for administering drug combinations
AU2003278039A1 (en) * 2002-10-22 2004-05-13 Merck Frosst Canada And Co. Nitric oxide releasing selective cyclooxygenase-2 inhibitors
AR042206A1 (en) 2002-11-26 2005-06-15 Novartis Ag Phenylacetic acid and derivatives
CA2515971A1 (en) 2003-02-19 2004-09-02 Altana Pharma Ag Nitrate esters of phenylaminothiophenacetic acid derivatives
DE602004021238D1 (en) 2003-03-05 2009-07-09 Merck Frosst Company Nitrogen monoxide releasing prodrugs of diaryl-2- (5h) furanoes as inhibitors of cyclooxygenase-2
RU2325189C2 (en) * 2003-03-20 2008-05-27 Фармация Корпорейшн Method and pharmaceutical composition for antiphlogistic agent delivery
US20050004098A1 (en) * 2003-03-20 2005-01-06 Britten Nancy Jean Dispersible formulation of an anti-inflammatory agent
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20050009931A1 (en) * 2003-03-20 2005-01-13 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
WO2005030224A1 (en) * 2003-09-26 2005-04-07 Nicox S.A. Nitrosylated analgesic and/or anti-inflammatory drugs having antiviral activity
WO2005063275A1 (en) * 2003-12-23 2005-07-14 Musc Foundaton For Research Development Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
US7622501B2 (en) 2004-01-27 2009-11-24 Merck Frosst Canada & Co. Nitric oxide releasing prodrugs of diaryl-2-(5H)-furanones as cyclooxygenase-2 inhibitors
JP2007520484A (en) * 2004-01-27 2007-07-26 メルク フロスト カンパニー Diaryl-2- (5H) -furanone nitric oxide releasing prodrug as cyclooxygenase-2 inhibitor
WO2005074536A2 (en) * 2004-01-30 2005-08-18 Eisai Co., Ltd. Compositions and methods using proton pump inhibitors
US8710038B2 (en) 2004-09-17 2014-04-29 Exelixis, Inc. Pyrazole kinase modulators and methods of use
WO2006040676A1 (en) * 2004-10-12 2006-04-20 Pharmacia & Upjohn Company Llc Nitrosated benzopyran compounds as novel cyclooxygenase-2 selective inhibitors
US20060111345A1 (en) * 2004-11-23 2006-05-25 Transform Pharmaceuticals, Inc. Pharmaceutical compositions comprising a selective COX-2 inhibitor and a diuretic
US7521435B2 (en) 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
WO2007016095A2 (en) * 2005-07-27 2007-02-08 Nitromed, Inc. Cyclooxygenase-2 selective inhibitor compounds comprising nitric oxide enhancing groups, compositions and methods of use
EP1915157A4 (en) 2005-08-02 2010-09-01 Nicox Sa Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
WO2007035879A2 (en) * 2005-09-20 2007-03-29 Galleon Pharmaceuticals Combination s-nitrosothiol-based pharmaceutical products for restoring normal breathing rhythm
CA2647859C (en) 2006-03-29 2016-01-05 Nitromed, Inc. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
EP2023894A4 (en) * 2006-04-25 2010-10-20 Applied Pharma Res Fixed combination dosage forms for the treatment of migraine
US7801502B2 (en) * 2006-12-18 2010-09-21 Aai Corporation Method for implementing continuous radio frequency (RF) alignment in advanced electronic warfare (EW) signal stimulation systems
EP2509942A2 (en) 2009-12-07 2012-10-17 Johns Hopkins University Bis-acylated hydroxylamine derivatives
US8409628B2 (en) 2010-02-04 2013-04-02 Penguin IP Holdings, Inc. Methods and compositions for oxygenation of skin to treat skin disorders
EP2598505B1 (en) 2010-07-28 2015-03-18 Bayer Intellectual Property GmbH Substituted imidazo[1,2-b]pyridazines
IT1402177B1 (en) * 2010-09-07 2013-08-28 Rottapharm Spa Nitroesteri of 1,5-diaryl-2-alkyl-3-substituted-pyrroles, selective inhibitors of cox-2 and nitrous oxide donors
UA111739C2 (en) 2011-04-07 2016-06-10 Байєр Інтеллектуал Проперті Гмбх Imidazopirydazyny inhibitors akt kinase
CA2899477C (en) * 2013-02-07 2019-09-17 The Regents Of The University Of Michigan Thromboresistant/bactericidal s-nitroso-n-acetylpenicillamine (snap)-doped nitric oxide release polymers with enhanced stability
US9862698B2 (en) 2014-12-16 2018-01-09 Adt Pharmaceuticals, Inc. Indenyl compounds, pharmaceutical compositions, and medical uses thereof
US20160168108A1 (en) 2014-12-16 2016-06-16 Adt Pharmaceuticals, Inc. Method of treating or preventing ras-mediated diseases

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE469451B (en) * 1991-06-28 1993-07-05 Anders Larsson Characterization of maengden bestaemning or mammalian cells by means of antibodies
IT1256345B (en) 1992-08-20 1995-12-01 Nitric esters of derivatives of 2- (2,6-di-halo-phenylamino) phenylacetic acid and process for their preparation
IT1256450B (en) 1992-11-26 1995-12-05 Soldato Piero Del Nitric esters with attivita 'drug and procedure for their preparation
US5604260A (en) 1992-12-11 1997-02-18 Merck Frosst Canada Inc. 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
DE69406903T2 (en) 1993-01-15 1998-04-09 Searle & Co 3,4-diarylthiophenes and analogs thereof, and their use as an anti-flamming agent
US5409944A (en) 1993-03-12 1995-04-25 Merck Frosst Canada, Inc. Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
DE69412109T2 (en) 1993-10-06 1999-01-21 Nicox Sa Salt acid ester with an anti-inflammatory and / or pain-relating effect and method for the production thereof
US5436265A (en) 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
CN1268614C (en) 1993-11-30 2006-08-09 G.D.瑟尔公司 Substituted pyrazolyl benzsulfamide compound for curing inflammation
CA2190087C (en) 1994-05-10 2005-08-02 Piero Del Soldato Nitro compounds and their compositions having anti-inflammatory, analgesic and anti-thrombotic activities
US5616601A (en) 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5620999A (en) 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
AT185797T (en) 1994-10-27 1999-11-15 Merck Frosst Canada Inc Stilb derivatives used as cyclooxygenase-2 inhibitors
IT1274175B (en) 1994-11-22 1997-07-15 Lab Alchemia Srl Process for the preparation of a pharmacologically active chemical combination
JP3181190B2 (en) 1994-12-20 2001-07-03 日本たばこ産業株式会社 Oxazole derivatives
JP2636819B2 (en) 1994-12-20 1997-07-30 日本たばこ産業株式会社 Oxazole-based heterocyclic aromatic compounds
WO1996023786A1 (en) 1995-01-31 1996-08-08 Merck Frosst Canada Inc. 5-methanesulfonamido-3h-isobenzofuran-1-ones as inhibitors of cyclooxygenase-2
AT223390T (en) 1995-02-13 2002-09-15 Searle & Co Substituted isoxazoles for treating inflammation
EA199700209A1 (en) 1995-04-04 1998-04-30 Глаксо Груп Лимитед IMIDAZO [1,2-a] PYRIDINE DERIVATIVES
US6051588A (en) 1995-04-19 2000-04-18 Nitromed Inc Nitroso esters of β-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5639780A (en) 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5604253A (en) 1995-05-22 1997-02-18 Merck Frosst Canada, Inc. N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en) 1995-05-22 1996-04-23 Merck Frosst Canada, Inc. N-benzyl-3-indoleacetic acids as antiinflammatory drugs
JPH11510485A (en) 1995-07-21 1999-09-14 ニィコメド・オーストリア・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Derivatives of benzenesulfonamide as inhibitors of the enzyme cyclooxygenase II
IT1276071B1 (en) 1995-10-31 1997-10-24 Nicox Ltd Composites activities to 'anti-inflammatory
US5733909A (en) 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
JP4004541B2 (en) 1996-02-01 2007-11-07 メルク フロスト カナダ リミテッド Alkylated styrene as a prodrug for COX-2 inhibitors
US5789413A (en) 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
ES2152648T3 (en) 1996-02-01 2001-02-01 Merck Frosst Canada Inc Difenylestilben as inhibiting propharmaces of the cox-2.
GB9602877D0 (en) 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
IT1282686B1 (en) 1996-02-26 1998-03-31 Nicox Sa Compounds that reduce the toxicity 'drug
ES2125161B1 (en) 1996-03-21 1999-11-16 Grupo Farmaceutico Almirall S New derivatives of 2- (3h) -oxazolona.
DE69715173T2 (en) 1996-03-29 2003-05-08 Merck Frosst Canada Inc Bisarylcyclobuten derivatives as a cyclooxygenase inhibitor
US5807873A (en) 1996-04-04 1998-09-15 Laboratories Upsa Diarylmethylidenefuran derivatives and their uses in therapeutics
US5908858A (en) 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
EP1288206B1 (en) * 1996-04-12 2008-09-17 G.D. Searle LLC Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
EP0900201A1 (en) 1996-04-23 1999-03-10 Merck Frosst Canada Inc. Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
US5756531A (en) 1996-04-30 1998-05-26 Abbott Laboratories Iminoxy derivatives of indole and indene compounds as inhibitors of prostaglandin biosynthesis
US5750558A (en) 1996-06-06 1998-05-12 Abbott Laboratories Oxime derivatives of indole and indene compounds as inhibitors of prostaglandin biosynthesis
US5677318A (en) 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
US5861419A (en) 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5776967A (en) 1996-07-26 1998-07-07 American Home Products Corporation Pyranoindole inhibitors of COX--2
US5830911A (en) 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
IT1288123B1 (en) 1996-09-04 1998-09-10 Nicox Sa Use of nitrates for urinary incontinence
US5821247A (en) * 1996-09-19 1998-10-13 Japan Energy Corporation Hydroquinone derivative and pharmaceutical use thereof
US5681842A (en) 1996-11-08 1997-10-28 Abbott Laboratories Prostaglandin synthase-2 inhibitors
EP0948493A1 (en) 1996-11-12 1999-10-13 American Home Products Corporation Indene inhibitors of cox-2
IT1295694B1 (en) 1996-11-14 1999-05-27 Nicox Sa Nitroxy derivatives for the preparation of medicaments having antithrombin activity
DK0946507T3 (en) 1996-12-10 2004-01-26 Searle & Co Substituted pyrrolyl compounds for the treatment of inflammation
EP0863134A1 (en) 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
TW492959B (en) 1997-04-18 2002-07-01 Merck & Co Inc Process for making 2-aryl-3-aryl-5-halo pyridines useful as cox-2 inhibitors
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
US6043232A (en) 1997-07-23 2000-03-28 Nitromed, Inc. Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
DK1005460T3 (en) 1997-08-22 2006-07-10 Abbott Lab Inhibitors of the biosynthesis of prostaglandin endoperoxide H synthase
EP1007515A1 (en) 1997-08-22 2000-06-14 Abbott Laboratories Arylpyridazinones as prostaglandin endoperoxide h synthase biosynthesis inhibitors
ES2231757T3 (en) 1997-09-05 2005-05-16 Glaxo Group Limited Pharmaceutical compositions that include derivatives of 2,3-diaril-pirazolo (1,5-b) piridazine.
EP1015431B1 (en) 1997-09-12 2005-04-20 Merck Frosst Canada & Co. 2-aminopyridines as inhibitors of cyclooxygenase-2
DE69825603T2 (en) 1997-09-12 2005-07-28 Merck Frosst Canada & Co, Kirkland 2,3,5-trisubstituted pyridines as inhibitors of cyclooxygenase-2
SE9703693D0 (en) 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
DE19753776A1 (en) * 1997-12-04 1999-06-10 Bosch Gmbh Robert Measuring device for contactless detection of an angle of rotation
IT1298338B1 (en) 1998-03-05 1999-12-20 Nicox Sa pharmaceutical compositions for the ulcer
IT1299198B1 (en) 1998-03-05 2000-02-29 Nicox Sa Nitrate salts of anti-ulcer drugs
TNSN99111A1 (en) * 1998-06-11 2005-11-10 Pfizer New sulfonylbenzene derivatives, process for their preparation and pharmaceutical compositions containing them.
SE9802333D0 (en) 1998-06-29 1998-06-29 Astra Pharma Prod Novel combination
IT1303672B1 (en) 1998-07-28 2001-02-23 Nicox Sa Upgrade active drugs nitrates in bone disorders
AU763000B2 (en) 1998-10-30 2003-07-10 Nicox S.A. Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use
JP2000164402A (en) 1998-11-27 2000-06-16 Rohm Co Ltd Structure of chip resistor
IT1307928B1 (en) 1999-01-26 2001-11-29 Nicox Sa A method for synthesizing esters nitroxymethylphenyl derivatidell'aspirina.
IT1308633B1 (en) 1999-03-02 2002-01-09 Nicox Sa Nitrossiderivati.
IT1311922B1 (en) 1999-04-13 2002-03-20 Nicox Sa pharmaceutical compounds.
IT1311923B1 (en) 1999-04-13 2002-03-20 Nicox Sa pharmaceutical compounds.
IT1311924B1 (en) 1999-04-13 2002-03-20 Nicox Sa pharmaceutical compounds.
IT1311921B1 (en) 1999-04-13 2002-03-20 Nicox Sa pharmaceutical compounds.
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
CA2393724A1 (en) * 1999-12-23 2001-06-28 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
US6681842B2 (en) * 2001-12-03 2004-01-27 Agilent Technologies, Inc. Cooling apparatus
AU5560001A (en) 2000-04-25 2001-11-07 Pharmacia Corp Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes
EP1534683A4 (en) * 2002-06-27 2005-08-24 Nitromed Inc Cyclooxygenase-2 selective inhibitors, compositions and methods of use
AU2003279622A1 (en) * 2002-06-28 2004-01-19 Nitromed, Inc. Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
JP2005538110A (en) * 2002-07-29 2005-12-15 ニトロメッド インコーポレーティッド Cyclooxygenase-2 selective inhibitors, compositions and methods of use
AU2003278039A1 (en) * 2002-10-22 2004-05-13 Merck Frosst Canada And Co. Nitric oxide releasing selective cyclooxygenase-2 inhibitors
DE602004021238D1 (en) * 2003-03-05 2009-07-09 Merck Frosst Company Nitrogen monoxide releasing prodrugs of diaryl-2- (5h) furanoes as inhibitors of cyclooxygenase-2

Also Published As

Publication number Publication date
CN100486573C (en) 2009-05-13
US7166618B2 (en) 2007-01-23
AP200202582A0 (en) 2002-09-30
US20030220228A1 (en) 2003-11-27
CN1434712A (en) 2003-08-06
US6649629B2 (en) 2003-11-18
US20070060571A1 (en) 2007-03-15
JP2003523958A (en) 2003-08-12
BR0017037A (en) 2003-06-10
US20010041726A1 (en) 2001-11-15
US7432285B2 (en) 2008-10-07
EP1246621A4 (en) 2004-11-24
NZ519781A (en) 2004-04-30
AU782971B2 (en) 2005-09-15
WO2001045703A1 (en) 2001-06-28
AU2592801A (en) 2001-07-03
KR20020067574A (en) 2002-08-22
RU2002119574A (en) 2004-01-10
CA2393724A1 (en) 2001-06-28
EP1246621A1 (en) 2002-10-09
MXPA02006312A (en) 2004-06-21
US20090099139A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
EG24433A (en) Novel benzolimidazole derivatives useful as antiproliferative agents
HK1047743A1 (en) New use and novel n-azabicyclo-amide derivatives.
SG2011035342A (en) Immunostimulatory sequence oligonucleotides and methods of using the same
HRP20060251B1 (en) Substituted oxasolidinones and their use
IL195076D0 (en) Improved skin substitutes and uses thereof
AU5900701A (en) Novel composition
AU2001255256A1 (en) Chemically modified novel erythropoietin stimulating protein compositions and methods
AU9481401A (en) Pumpcn compositions and uses thereof
ZA200500887B (en) Use of and some novel imidazopyridines.
ZA200501082B (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
HU0201020A3 (en) Novel sulfonamide compounds and uses thereof
HU0401534A3 (en) Modified factor ix
EP1539729A4 (en) Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
HU0202797A3 (en) Compositions having improved stability
HRP20040347A2 (en) Keratynocites which may be used as biologically ac
EP1463742A4 (en) Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
PL349282A1 (en) Cosmetic composition
HU0202275A3 (en) Mousse-forming shampoo compositions
IL158388D0 (en) Novel arylheteroalkylamine derivatives
AU2003293529A1 (en) Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
HK1067128A1 (en) Beta-carbolin derivatives as ptp-inhibitors
PL211762B1 (en) Novel use
IL164806D0 (en) Ä1,4ÜDiazepino Ä6,7,1-ijÜquinoline derivatives as anti psychotic and antiobesity agents
HK1042321A1 (en) Novel desensitized aspartokinase
HK1046512A1 (en) Cement composition